Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Skin Cancer Oncologists (US)

November 27, 2006
The favorite drug
By a GLG Expert Contributor
Analysis of: FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy (www.ptcommunity.com)
1. Herceptin is one of the favorite drugs used by oncologists2. Optimal schedule and length is not clear3. Role of additional testing is not established4. Competition is around the corner
November 20, 2006
The drug is innocent, the management sucks
By a GLG Expert Contributor
Analysis of: Cell Therapeutics: Xyotax faces more developmental delays (www.pharmaceutical-business-review.com)
Implications: 1. Drug will be delayed further2. Abraxane and Epothilone B will be approved. 3. If management understood that approach of early 80s does not work now, the drug would be available on market years ago.  
November 20, 2006
Effectiveness vs cost –effectiveness
By a GLG Expert Contributor
Analysis of: NICE rejects use of cancer drug Tarceva (www.pharmaceutical-business-review.com)
1. The first working drug will not be approved because it is too expensive.2. Narrow indication: never smoker, EGFR (+) would likely be approved if submitted, but that would establish the precedent and affect many other drugs3. US regulatory authorities may follow suite.

Previous Page : 1 2 3 431 to 33 of 33

Analytics


Generated at 2009-01-09T13:00:20.343